Neoleukin Therapeutics, Inc. Announces Management Changes
Also on February 25, 2022, the Board appointed Martin Babler, a member of the Board, to serve as Chairperson of the Compensation Committee, effective
as of the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.59 USD | +1.43% |
|
+12.43% | +119.76% |
Jun. 11 | Baird Initiates Neurogene With Outperform Rating, $54 Price Target | MT |
Jun. 03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
1st Jan change | Capi. | |
---|---|---|
+119.76% | 553M | |
+40.80% | 53.67B | |
+34.46% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |